St. Jude Durata ICD Lead Insulation Breaches Probed In Hauser Study
This article was originally published in The Gray Sheet
Executive Summary
MAUDE analysis suggests some trouble spots for St. Jude’s newer Optim-insulated ICD leads, according to researchers. But the company says the overall data shows the products to be as safe and reliable as competitors’ offerings.
You may also be interested in...
FDA Orders St. Jude To Expand Surveillance Of ICD Leads, Including Durata
The agency announced Section 522 post-market surveillance orders that target St. Jude Medical’s recalled Riata leads, as well as the currently marketed Durata leads.
St. Jude Persists In Effort To Correct The Record On Riata Study
“We will continue to work through the proper channels with the HeartRhythm journal and the Heart Rhythm Society to ensure there is an appropriate presentation of validated, accurate information,” a company spokeswoman said.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.